ABBOTT LABORATORIES Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax
ABBOTT LABORATORIES (ABT) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax of -$11.00 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-04-29.
Financial Statements › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax · last filed 2026-04-29
- ABBOTT LABORATORIES other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2026-03-31 was -$11.00M, a 134.38% decline year-over-year.
- ABBOTT LABORATORIES other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-12-31 was $10.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-09-30 was -$6.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), foreign currency translation adjustment, tax for the quarter ending 2025-06-30 was $26.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2025 was $62.00M.
- ABBOTT LABORATORIES other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2024 was $0.00.
- ABBOTT LABORATORIES other comprehensive income (loss), foreign currency translation adjustment, tax for fiscal 2023 was $0.00.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$11.00M 10-Q · filed 2026-04-29 | -$1.00M derived: sum of 2 quarters · filed 2026-04-29 | -$7.00M derived: sum of 3 quarters · filed 2026-04-29 | $19.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-12-31 | $10.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $4.00M derived: sum of 2 quarters · filed 2026-02-20 | $30.00M derived: sum of 3 quarters · filed 2026-02-20 | $62.00M 10-K · filed 2026-02-20 |
| 2025-09-30 | -$6.00M 10-Q · filed 2025-10-29 | $20.00M derived: sum of 2 quarters · filed 2025-10-29 | $52.00M 10-Q · filed 2025-10-29 | $52.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-06-30 | $26.00M 10-Q · filed 2025-07-30 | $58.00M 10-Q · filed 2025-07-30 | $58.00M derived: sum of 3 quarters · filed 2026-04-29 | $58.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2025-03-31 | $32.00M 10-Q · filed 2026-04-29 | $32.00M derived: sum of 2 quarters · filed 2026-04-29 | $32.00M derived: sum of 3 quarters · filed 2026-04-29 | $32.00M derived: sum of 4 quarters · filed 2026-04-29 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $0.00 derived: sum of 2 quarters · filed 2026-02-20 | $0.00 derived: sum of 3 quarters · filed 2026-02-20 | $0.00 10-K · filed 2026-02-20 |
| 2024-09-30 | $0.00 10-Q · filed 2025-10-29 | $0.00 derived: sum of 2 quarters · filed 2025-10-29 | $0.00 10-Q · filed 2025-10-29 | |
| 2024-06-30 | $0.00 10-Q · filed 2025-07-30 | $0.00 10-Q · filed 2025-07-30 | ||
| 2024-03-31 | $0.00 10-Q · filed 2025-04-30 | |||
| 2023-12-31 | $0.00 10-K · filed 2026-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |